What do systematic reviews say?

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 165 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 165 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids showed no clear difference in ambulation compared with moderate‐dose or no corticosteroids (low certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 1.08 [0.81, 1.45]
  3 studies · 105 participants
  Low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 1.11 [0.24, 5.05]
  1 study · 57 participants
  Low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids showed no clear difference in pain reduction compared with moderate‐dose or no corticosteroids (low certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.62, 1.2]
  1 study · 25 participants
  Low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids showed no clear difference in urinary continence One week after treatment compared with moderate‐dose or no corticosteroids (low certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 1.18 [0.66, 2.13]
  1 study · 34 participants
  Low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

The review found no eligible studies for this question.

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 8.02 [1.03, 62.37]
  2 studies · 77 participants
  Moderate

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

The review found no eligible studies for this question.

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic corticosteroids vs placebo

• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 114 participants
  Very low

Systemic corticosteroids vs placebo

• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Very low
• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 113 participants
  Very low

Systemic corticosteroids vs placebo

• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 157 participants
  Very low

Systemic corticosteroids vs placebo

The review found no eligible studies for this question.

• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic corticosteroids vs placebo

• Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 173 participants
  Very low